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Ca2þ and the cell-surface calcium sensing receptor (CaSR) constitute a novel and robust ligand/receptor system in
regulating the proliferation and differentiation of colonic epithelial cells. Here we show that activation of CaSR by
extracellular Ca2þ (or CaSR agonists) enhanced the sensitivity of human colon carcinoma cells to mitomycin C (MMC)
and fluorouracil (5-FU). Activation of CaSR up-regulated the expression of MMC activating enzyme, NAD(P)H:quinone
oxidoreductase 1 (NQO-1) and down-regulated the expression of 5-FU target, thymidylate synthase (TS) and the anti-
apoptotic protein survivin. Cells that were resistant to drugs expressed little or no CaSR but abundant amount of
survivin. Disruption of CaSR expression by shRNA targeting the CaSR abrogated these modulating effects of CaSR
activation on the expression of NQO1, TS, survivin and cytotoxic response to drugs. It is concluded that activation of
CaSR can enhance colon cancer cell sensitivity to MMC and 5-FU and can modulate the expression of molecules
involved in the cellular responses to these cytotoxic drugs.  2008 Wiley-Liss, Inc.
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INTRODUCTION
The human parathyroid calcium sensing receptor
(CaSR) can sense minute changes in extracellular
Ca2þ concentration and respond to tightly regulate
systemic Ca2þ homeostasis by coordinating the
secretion of endocrine hormones [1]. Human
colonic epithelium and colon carcinoma cell lines
express CaSR [2–4]. The function of CaSR in the
colon, however, is intimately associated with growth
and differentiation control [2–6]. In normal human
colonic crypts, CaSR expression is restricted to
differentiating epithelial cells as these cells migrate
from the bottom of the crypts towards the apex. A
relatively high level of CaSR expression is found in
cells at the apex of a crypt where they are fully
differentiated, nonproliferating and ready to under-
go apoptosis [4]. Rapidly proliferating stem cells at
the base of a crypt, however, do not express CaSR [4].
Thus, CaSR expression in human colonic crypts is
linked to differentiation and reduction of prolifer-
ation. Carcinomas, on the other hand, show a
different pattern of CaSR expression. Differentiated
carcinoma (still retaining some glandular or crypt
structures) express a relatively lower level of CaSR
while a loss of CaSR expression is found in undiffer-
entiated carcinoma (with no glandular or crypt
structure) or in the invasive front of a differentiated
carcinoma [3,4]. Because transformation of colonic
mucosa is attributable to blockade of terminal
differentiation resulting in regional expansion of
proliferation [7] and CaSR expression is linked to
normal differentiation while its loss of expression is
associated with progression, we hypothesize that
CaSR is a robust regulator of proliferation and
differentiation in human colonic epithelial cells
and that this function of CaSR is directly linked to
how colon carcinoma cells respond to cytotoxic
drugs.
When the culture medium (containing low Ca2þ)
of human colon carcinoma cell lines were changed to
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medium containing a physiologic concentration of
1.4 mM Ca2þ, they assume a more differentiated and
benign phenotype with a change in cell morphology,
reduction in growth and invasive capability [3–6].
This ligand/receptor system modulates differentia-
tion control pathways that underlie the changes
in biologic phenotype. Most prominent of these
pathways are the E-cadherin/b-catenin/wnt signal
pathway and cell cycle control pathway [3–6].
Because degree of differentiation in colon carcino-
mas can influence survival and differentiated carci-
nomas express CaSR [3,4,8,9], we hypothesize that
this ligand/receptor system could modulate cellular
sensitivity to cytotoxic drugs. The goal of this study
was to determine if activation of CaSR by extra-
cellular Ca2þ could modulate the cytotoxic response
of human colon carcinoma cells to fluorouracil
(5-FU) and mitomycin C (MMC) and assess the
potential mechanisms underlying such modulation.
We chose 5-FU and MMC in this study because
5-FU is a drug of choice for treating colon cancer [10]
while the alkylating agent MMC possesses marginal
activity against this disease [11]. The molecular
target of 5-FU is thymidylate synthase (TS), a key
enzyme in the de novo synthesis of DNA [10].
Increased TS expression in tumors is an underlying
mechanism by which tumor cells can escape from
the toxic effect of 5-FU and become drug resistance
[10]. MMC is an anti-tumor quinone which requires
bioreductive activation to alkylate and crosslink
cellular DNA efficiently [11]. The cytosolic NAD(P)H:
quinone oxidoreductase 1(NQO-1 [also known as
DT-diaphorase]) is an important enzyme in media-
ting the bioreductive activation of MMC and
decreased bioreductive activation of MMC is asso-
ciated with the development of MMC resistance
[12,13]. In addition to drug targets and drug
activation, a critical determinant underlying sensi-
tivity or resistance to cytotoxic drugs is the ease in
which tumor cells undergo drug-induced apoptosis
[14–16]. Resistance to the induction of apoptosis is a
well-defined characteristic of drug resistant cancer
cells. Survivin is a well-known anti-apoptotic protein
and its function in blocking apoptosis and promot-
ing drug resistance is well-characterized [17–19].
In this report, we showed that activation of CaSR
enhanced the cytotoxic response of human colon
carcinoma cells to MMC and 5-FU by modulating
the expression of molecules that are intimately
associated with drug sensitivity or resistance. We
also found that drug resistant cells did not express
CaSR but expressed a relatively high level of survivin.
MATERIALS AND METHODS
Cell Culture and Cytotoxicity Assays
Human colon carcinoma CBS, Moser, Fet and
SW480 cells were maintained in SMEM medium
(Ca2þ-free, Sigma, St. Louis, MO) supplemented with
sodium bicarbonate, peptone, vitamins, amino acids
and 5% fetal bovine serum as described previously
[3,4]. Because fetal bovine serum contains approx-
imately 3.5–4 mM Ca2þ, the culture medium con-
tained a low concentration of Ca2þ (0.175–0.2 mM).
To assess the effect of Ca2þ on the cytotoxic response
to drugs, the medium of actively growing cells was
replenished with medium containing a physiologic
concentration of 1.4 mM Ca2þ, or a range of Ca2þ
concentrations as indicated in the figures and 30 mM
MMC or 15 mM 5-FU. The medium of a parallel set of
cultures was replenished with medium only con-
taining drugs without the addition of exogenous
Ca2þ. The medium of control cultures was replen-
ished with regular culture medium without drugs or
exogenous Ca2þ. Cells were then incubated at 378C
in a CO2 incubator for the time periods as indicated
in the figure legends. MMC was purchased from
Roche Diagnostics (Indianapolis, IN) and 5-FU was
purchased from Sigma.
Trypan blue dye exclusion [20] and MTS assays
were used to determine the cytotoxic response to
MMC or 5-FU. Dye exclusion assay was performed in
24-well culture plates with equal number of cells
seeded into each well. Briefly, control cells and cells
treated with drugs in the absence or presence of
exogenous Ca2þwere detached by trypsinization and
suspended in phosphate buffered saline containing
0.4% (w/v) trypan blue. The number of viable
(unstained, dye excluding) cells were determined
with the aid of a hemocytometer and the results were
expressed as percent of cells killed by comparison
to untreated control cultures. The cells from each
culture well were routinely counted three times and
the average of these values was taken to represent
the value from one well. The results presented here
represent the mean and standard error of the mean of
three independent determinations from three sepa-
rate experiments.
MTS assay was performed using a CellTiter96TM
AQueous Assay (MTS) kit (Promega, Madison, WI)
according to instructions provided by the manufac-
turer. Briefly, 5103 cells were seeded into each well
of 96-well culture plates and incubated at 378C in
a CO2 incubator for 24 h. The medium was then
replenished with medium containing 30mM MMC or
15 mM 5-FU in the absence or presence of a range of
Ca2þ concentrations as shown in Figure 1B or in the
absence or presence of Gd3þ (25 mM) or neomycin
(350 mM) as shown in Figure 1C. Cells were then
incubated at 378C in the CO2 incubator for 24 h. The
cells were then rinsed with plain SMEM medium
followed by the addition of CellTiter96TM Aqueous
One Solution Reagent to the culture wells according
to manufacturer’s instruction. The absorbance at
490 nm was then recorded using a mQuant Micro-
Plate Reader (Bio-Tek Instruments, Inc., Winooski,
VT). Results were expressed as percent cells killed by
comparison to untreated control cultures. Results
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shown represent the mean and standard error of the
mean of three independent experiments.
Construction of shRNA Expression Vector (shRNA-CaSR)
Targeting the CaSR, Transfection, Selection and
Development of Stable Transfectants
shRNA-CaSR expression vector was constructed in
pRNA-U6.1/Hygro under the control of U6 promoter
and contains a hygromycin-resistant gene for the
selection of stable transfectants for hygromycin
resistance. shRNA-CaSR was purchased from Gen-
Script Co. (Piscataway, NJ). The target sequence—
ATCCCGCTCCGGCCTTGATTTGAGATCTTGATAT-
CCGGATCTCAAATCAAGGCCGGAGTTTTTTCCAAA—
was designed by the company’s shRNA Target Finder
and DesignTool. The underlined sequence repre-
sents the target sequence of CaSR inserted into
pRNA-U6.1/Hygro. pRNA-U6.1/Neo/Ctrl (GenScript
Co.) with a scrambled insert was used as a control
vector (shRNA-Ctrl) in transfection experiments.
Plasmids shRNA-CaSR or shRNA-Ctrlwere transfect-
ed into CBS carcinoma cells using LipofectamineTM
2000 (Invitrogen Life Technologies, Frederick, MD)
according to the manufacturer’s protocol. The stable
shRNA-CaSR or shRNA-Ctrl transfectants were estab-
lished by selection of the cells with 200 mg/ml of
hygromycin B for shRNA-CaSR transfected cells or
500 mg/ml of G418 for shRNA-Ctrl transfected cells.
Clones of stable transfectants were obtained by the
use of cloning cylinders. Transfectants were rou-
tinely cultured in SMEM medium containing 50 mg/
ml of hygromycin B (shRNA-CaSR transfected) or
200 mg/ml of G418 (shRNA-Ctrl transfected).
Immunocytochemistry and Quantitation of the
Preponderance of CaSR and Survivin Expression
Before and After Drug Treatment
Cells were cultured on glass cover slips placed
in 24-well cultured plates. Equal number of cells
(1105) was seeded into each well. Cells were
cultured to 70% confluence and then treated with
MMC or 5-FU with the concentrations of drugs and
duration of treatments as indicated in the figures.
Immunocytochemical staining with anti-human
CaSR (Affinity BioReagents, Golden, CO) or anti-
human survivin antibodies (R&D Systems, Inc.,
Minneapolis, MN) was performed using the ABC kit
Figure 1. Activation of CaSR by extracellular Ca2þ and the CaSR
agonists Gd3þ and neomycin enhances the cytotoxic response of
human colon carcinoma CBS, Moser, Fet and SW480 cells to MMC
and 5-FU. (A) Trypan blue dye exclusion method [20] was used
to determine the cytotoxic response to MMC or 5-FU and was
performed in 24-well culture plates as described in Materials and
Methods Section. Cells were exposed to drugs for 24 or 48 h in
culture medium (without the addition of exogenous Ca2þ) or in
medium containing exogenous Ca2þ (1.4 mM). Results are expressed
as percent cells killed by comparison with control cultures and
represent the mean and standard error of the mean of three
independent experiments. Hollow bars, cells cultured in medium
without exogenous Ca2þ. Solid bars, cells cultured in medium
containing Ca2þ (1.4 mM). Asterisk (*) indicates P< 0.01 compared
to controls. (B) MTS assays were performed in 96 well culture plates
as described in Materials and Methods Section to determine the
cytotoxic response to MMC and 5-FU. Cells were exposed to drugs
for 24 h in culture medium (without the addition of exogenous Ca2þ)
or in medium containing different exogenous Ca2þ concentrations
as indicated. The results are expressed as percent cells killed by
comparison with control cultures. The results presented here
represent the mean and standard error of three independent
experiments. (C) MTS assays, in 96-well plates, were used to
determine the effects of Gd3þ and neomycin (Neo) on the cytotoxic
response to MMC and 5-FU. Cells were exposed to drugs for 24 h in
plain medium or in medium containing 25 mM Gd3þ or 350 mM Neo.
Results are expressed as percent cells killed by comparison with
control cultures in the absence of drugs. The results presented
here represent the mean and standard error of three independent
experiments. Hollow bars, cells cultured in Gd3þ and Neo-free
medium as controls. Cross bars, cells cultured in medium containing
Gd3þ (25 mM). Solid bars, cells cultured in medium containing Neo
(350 mM). Asterisk (*) indicates P<0.01 compared with control.
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(Vector Laboratories, Inc., Burlingame, CA) accord-
ing to the manufacturer’s instruction. Briefly, cells
on cover slips were rinsed with phosphate-buffered
saline (PBS) and fixed with 4% paraformaldehyde
for 10 min at 48C. Membrane permeabilization was
accomplished by treatment with 100% methanol at
208C for 5 min. Cellular endogenous peroxidase
activity was then quenched with PBS containing
0.3% serum and 0.3% H2O2 for 5 min at room
temperature. Non specific peroxidase activity was
further blocked with normal blocking serum (sup-
plied with the ABC kit’s manufacturer) for 20 min at
room temperature.
Both primary antibodies at a dilution of 1:2000 in
PBS were used in these experiments. Cells were
incubated with primary antibodies (PBS in the
absence of primary antibodies and blocking peptides
in the presence of antibodies served as controls) for
30 min at room temperature, washed and incubated
with biotinylated secondary antibody, ABC reagent
and DAB substrate according to the manufacturer’s
protocol. Cells were then counterstained with
Mayer’s Hematoxylin Solution (Sigma).
Immunostaining of the cells was evaluated and
scored under a phase contrast microscope. One
hundred cells from each of a set of triplicate slides
from one experiment was scored as positive or
negative according to the relative intensity of
staining. An example of the selection criterion for
CaSR and survivin staining is shown in Figure 2A and
C, respectively.
Western Blots
Western blottings were performed essentially as
previously described [3,4]. Total cell lysates were
prepared in lysate buffer (50 mmol/L Tris pH 7.5,
100 mmol/L NaCl, 1.0 mmol/L EDTA, 0.5% NP40,
Figure 2. CaSR and survivin expression in drug resistant cells.
Immunocytochemical methods were used to assess the preponder-
ance of CaSR and survivin expression in cells that survived treatment
with MMC or 5-FU. Cells were cultured on coverslips placed in
24-well culture plates and treated with MMC or 5-FU for 24 h as
described in Materials and Methods Section. Control cells were
similarly cultured but without drugs. Attached viable cells that
survived drug treatments were then processed for immunocyto-
chemical staining with anti-CaSR or anti-survivin antibodies.
(A) Example of a cell that was scored CaSR positive (CaSRþ) and
example of a cell that was scored CaSR negative (CaSR).
(B) Preponderance of CaSR positive and CaSR negative cells
following exposure to MMC or 5-FU. Approximately 100 cells per
view in the microscope were scored according to this criterion.
Hollow bars, CaSR positive cells; solid bars, CaSR negative cells. Error
bars, standard error of the mean of three independent experiments.
(C) Example of a cell that was scored survivin negative (survivin)
and example of a cell that was scored survivin positive (survivinþ).
(D) Preponderance of survivin positive and survivin negative cells
following exposure to MMC or 5-FU. Approximately 100 cells per
view in the microscope were scored according to this criterion.
Hollow bars, survivin positive cells; solid bars, survivin negative
cells. Error bars, standard error of the mean of three independent
experiments.
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0.5% Triton X-100, 2.5 mmol/L sodium orthovana-
date, 10 mL/mL protease inhibitor cocktail (EMD
Chemicals Inc., San Diego, CA) and 1 mmol/L PMSF).
Protein concentrations were determined by the Bio-
Rad dye binding assay (Bio-Rad, Hercules, CA).
Cellular proteins were fractionated by reducing
SDS-PAGE and electrophoretically transferred onto
nitrocellulose membranes, blocked (5% nonfat dried
milk in 1 TBS buffer containing 0.1% Tween 20)
and immunostained with primary antibodies. Pri-
mary antibodies used were the above described anti-
human CaSR (which recognizes a 120-kDa CaSR
band) and anti-human survivin antibodies; anti-
human TS (Invitrogen, Carlsbad, CA) and anti-
human NQO-1 (IMGENEX Co., San Diego, CA).
Horseradish peroxidase–conjugated secondary anti-
bodies in conjuction with chemiluminescence
detection and the FUJIFILM LAS-3000 system (Fuji-
film Life Science, Stamford, CT) were used to visual-
ize the binding of primary antibodies to immobilized
proteins of interest on the membranes. b-Actin
expression (using anti-human b-actin antibody
(Abcam Inc., Cambridge, MA)) was used as internal
controls for equal protein loading.
Quantitative analysis of protein expression was
performed using Multi Gauge-Image software
installed in the FUJIFILM LAS-3000 system. Densito-
metric fold increase or decrease in protein expres-
sion, by comparison with control lanes, was
calculated. The numbers on the blots represent fold
differences by comparison with control lanes with
an assigned value of 1.
RESULTS
Modulation of Cytotoxic Response to MMC and 5-FU by
Extracellular Ca2þ and CaSR Agonists
Figure 1A shows that extracellular Ca2þ, in phys-
iologic concentration of 1.4 mM, could enhance
the sensitivity of human colon carcinoma CBS,
Moser, Fet and SW480 cells to MMC and 5-FU. In
the presence of exogenous Ca2þ, the percent of cells
killed after treatment with MMC or 5-FU for 24 h, was
almost doubled that of cells killed in the absence of
Ca2þ (Figure 1A). More cells (either in the presence or
absence of Ca2þ) were killed after exposure to drugs
for 48 h. The magnitude of the differential response
observed between Ca2þ and control conditions
had diminished after 48 h of exposure to drugs
(Figure 1A). Nevertheless, this observed differences
in the cytotoxic response between these 2 groups,
after 48 h of drug treatment, were still of statistical
significance (unpaired Student’s t-test. P<0.05).
Figure 1B shows the promotion of the cytotoxic
response to MMC and 5-FU over a range of extra-
cellular Ca2þ concentrations (0.005–5 mM). Con-
centrations higher than physiological were more
effective in enhancing the sensitivity of these colon
carcinoma cells to MMC and 5-FU.
If activation of CaSR by extracellular Ca2þ could
promote sensitivity to MMC and 5-FU, then activa-
tion of CaSR by other receptor agonists such as Gd3þ
or neomycin should have similar effects. Figure 1C
shows that both Gd3þ and neomycin enhanced the
sensitivity of these colon carcinoma cells to MMC
and 5-FU.
Lack of CaSR Expression and High Level of Survivin
Expression Correlates With Resistant to MMC and 5-FU
Because CaSR functions to sense extracellular Ca2þ
concentrations and is activated by extracellular Ca2þ
[1], we hypothesized that CaSR mediates the action
of extracellular Ca2þ in modulating the cellular
responses to drugs. Because the anti-apoptotic
protein survivin plays an important role in drug
resistance, we also hypothesized that drug resistant
cells express a relatively high level of survivin. We
next focused on the role of CaSR and survivin in
drug resistance in the CBS cells, a moderately differ-
entiated human colon carcinoma cell line which is
quite responsive to the growth-inhibitory and differ-
entiation-promoting effect of extracellular Ca2þ and
is one of the better characterized cell line in terms
of its responsiveness to extracellular Ca2þ [3–6].
In addition, we were able to generate stable CaSR
knocked-down cells in the CBS line, which should
offer a greater ease in the elucidation of underlying
mechanisms. Immunocytochemical analyses of
CaSR and survivin expression showed that the
expression of these molecules in the CBS line was
heterogeneous and expression levels ranged from no
expression to intermediate and high level of expres-
sion. Examples of CaSR negative, CaSR positive,
survivin positive and survivin negative cells are
shown in Figure 2A and C. We first determined the
preponderance of CaSR and survivin expression by
immunocytochemistry in the CBS cells and in drug
resistant cells that survived a 24 h exposure to MMC
or 5-FU. A majority of the CBS cells (before drug
treatment) was CaSR positive while only about 10–
20% of the cells were CaSR negative (Figure 2B) as
defined by the criterion shown in Figure 2A. A
progressive reversal of this proportion was observed
with surviving cells exposed to increasing concen-
tration of drugs (Figure 2B). Seventy to 75% of the
cells that survived MMC (30 mM) and 5-FU (15 mM)
were now CaSR negative (Figure 2B). Before drug
exposure, about 60% of the CBS cells were survivin
positive. The proportion of survivin positive cells
rose to 90% in cells that survived treatment with
MMC (30 mM) and 5-FU (15 mM) (Figure 2D).
We then used Western blots to determine and
confirm the level of CaSR and survivin expression in
cells that survived treatment with MMC or 5-FU.
Cells were treated with the cytotoxic drugs for 2, 6,
24, and 48 h, respectively and cell lysates were
prepared from viable attached cells that had initially
survived drug treatment (i.e., drug resistant cells) for
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western blottings. Figure 3A shows a progressive
decrease in CaSR expression in response to progres-
sive increase in the duration of drug exposure. We
observed a decrease in CaSR expression, in cells that
survived drug treatment, as early as after 2 h of
exposure to drugs while an almost total loss of CaSR
expression was observed in cells that survived 48 h of
drug exposure (Figure 3A). The opposite was true in
regard to the expression of survivin. Figure 3B shows
a progressive increase in survivin expression in drug
resistant cells in response to the progressive increase
in the duration of drug exposure. A high level of
survivin expression was observed in cells that
survived 24 and 48 h of exposure to MMC or 5-FU
(Figure 3B). The results of these experiments, taken
together, show that cells that survived drug treat-
ment and were, therefore, relatively drug resistance
were predominantly CaSR negative and expressed a
high level of survivin while the CaSR positive cells
were relatively sensitive to drugs and were first killed
by drugs. These results also suggest that CaSR is
involved in modulating the effects of extracellular
Ca2þ.
Extracellular Ca2þ and Gd3þ Modulates the Expression of
NQO-1, TS and Survivin Through the CaSR
In a final series of experiments, we determined the
potential mechanisms by which Ca2þ or the CaSR
agonist Gd3þ could modulate the cellular sensitivity
to MMC and 5-FU and whether CaSR function was
required for this modulation. It is known that the
bioreductive activation of MMC is required for
the anti-tumor effect of MMC and that inefficient
reductive activation of MMC is associated with MMC
resistance [11–13]. It is also known that TS is the
major cellular target of 5-FU and increased TS
expression underlies 5-FU resistance [10] while
increased expression of the anti-apoptotic protein
survivin can confer resistance to a variety of anti-
cancer drugs [14,17]. If extracellular Ca2þ or Gd3þ
could modulate cellular sensitivity to MMC and 5-
FU, we hypothesized that extracellular Ca2þ or Gd3þ
modulates the level of expression of NQO-1, TS and
survivin. In addition, we hypothesized that these
modulating effects of extracellular Ca2þ or Gd3þ
acted through the CaSR.
We used a shRNA approach targeting the CaSR to
determine the role of CaSR in mediating the action of
extracellular Ca2þ and Gd3þ. Expression of shRNA-
CaSR in the CBS cells (but not control vector
transfected cells) effectively disrupted the expression
of CaSR (Figure 4A). In the parental cells, extrac-
ellular Ca2þ down-regulated the expression of TS and
survivin and up-regulated the expression of NQO-1
(Figure 4B, lanes 1–2). Interestingly, cells with
disrupted CaSR expression had a higher level of TS
and survivin expression by comparison with the
parental control cells (Figure 4B, lanes 1 and 3).
Disrupting CaSR expression by shRNA-CaSR abro-
gated the modulating effect of extracellular Ca2þ on
Figure 3. Western blot analyses of the expression of CaSR and
survivin after treatment with MMC or 5-FU. Western blottings of cell
lysates were performed as previously described (3–4). Treatment of
cells with MMC or 5-FU was performed as described in Materials and
Methods Section with the exception that cells were cultured in
25 cm2 culture flasks. Cell lysates were prepared from viable
attached cells after various time of exposure to drugs as indicated in
the figure. (A) CaSR expression. Lane 1, untreated control CBS cells;
lane 2, cells treated with MMC; lane 3, cells treated with 5-FU. (B)
Survivin expression. Lane 1, untreated controls; lane 2, cells treated
with MMC; lane 3, cells treated with 5-FU. Number on top of each
band indicate the densitometric fold increase or decrease in protein
expression compared with control lanes (lane 1).
CaSR AND COLON CANCER 207
Molecular Carcinogenesis
the expression of TS, NQO-1 and survivin (Figure 4B,
lanes 3–4) and circumvented the enhancing effect
of extracellular Ca2þ on the cytotoxic responses to
MMC and 5-FU (Figure 5A). Thus, extracellular Ca2þ
down-regulated the expression of TS and survivin,
up-regulated the expression of NQO-1 and enhanced
cellular sensitivity to 5-FU and MMC. Knocking
down CaSR expression abrogated these modulating
effects of extracellular Ca2þ. Likewise, Gd3þ down-
modulated the expression of TS and survivin and up-
regulated the expression of NQ0-1 in the parental
control cells but not in CaSR knocked-down cells
(Figure 4C). Disrupting CaSR expression also circum-
vented the enhancing effect of Gd3þon the cytotoxic
responses to MMC and 5-FU (Figure 5B).
DISCUSSION
The chemopreventive properties of Ca2þ in colon
cancer are well-established [21,22] and are the
subject of much recent interest. How Ca2þ acts at
the molecular level to suppress or delay colon
carcinogenesis, that is, its mechanism of chemo-
preventive action, is not understood. Recent studies
suggest that CaSR and extracellular Ca2þ function
Figure 4. Disruption of CaSR expression blocks the modulating
effect of Ca2þ and Gd3þ on the expression of TS, NQO1 and survivin
(A) Stable transfection with a shRNA expression vector targeting
the CaSR (shRNA-CaSR) disrupted the expression of CaSR. Lane1,
Parental control cells; lane 2, Control (shRNA-Ctrl) transfected cells;
lane 3, shRNA-CaSR transfected cells. (B) Disruption of CaSR
expression blocks the modulating effect of Ca2þ on the expression
of TS, NQO1 and survivin. Lane 1, parental control cells; lane 2, cells
exposed to 1.4 mM Ca2þ for 24 h; lane 3, shRNA-CaSR transfectants;
lane 4, shRNA-CaSR transfectants exposed to 1.4 mM Ca2þ for 24 h.
(C) Disruption of CaSR expression blocks the modulating effect of
Gd3þ on the expression of TS, NQO1 and survivin. Lane 1, parental
control cells; lane 2, cells exposed to 25 mM gadolinium for 24 h; lane
3, shRNA-CaSR transfectants; lane 4, shRNA-CaSR transfectants
exposed to 25 mM gadolinium for 24 h. Numbers on top of each
band indicate the densitometric fold increase or decrease in protein
expression compared with controls (lane 1).
Figure 5. Disruption of CaSR expression blocks the enhancing
effect of Ca2þ and Gd3þ on the cytotoxic response to MMC and
5-FU. (A) These experiments were performed as described in the
legends to Figure 1A in medium containing 1.4 mM Ca2þ. Parental
cells, shRNA-Ctrl and shRNA-CaSR transfectants were exposed to
MMC or 5-FU for 24 h and their cytotoxic response to drugs
evaluated. Hollow bars, parental control cells. Slashed bars, control
transfectants. Solid bars, shRNA-CaSR transfectants. Asterisk (*)
indicates P< 0.01 compared to controls without drugs. (B) These
experiments were performed as described in the legends to Figure
1C in medium containing 25 mM Gd3þ. Parental cells, shRNA-Ctrl
and shRNA-CaSR transfectants were exposed to MMC or 5-FU for 24
h and their cytotoxic response to drugs evaluated. Hollow bars,
parental CBS cells. Slashed bars, control transfectants. Solid bars,
shRNA-CaSR transfectants. Asterisk (*) indicates P< 0.01 compared
with CBS control cells.
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together to promote differentiation and suppress the
malignant properties of human colon adenocarci-
noma cells in vitro and that the mechanisms of
action of this ligand receptor system are intimately
associated with differentiation control in colonic
epithelial cells. These mechanisms include the
promotion of E-cadherin expression and suppression
of b-catenin/wnt pathway, blockade of cell-cycle
progression and the restoration of cell–cell and cell–
matrix adhesion [3–6]. Correlative immunohisto-
chemical studies using pathological specimens of
human colon also suggest that CaSR is a key player
in proliferation and differentiation in the colonic
epithelium. CaSR expression is associated with
differentiation and suppression of b-catenin/wnt
pathway while loss of CaSR expression is associated
with malignant progression and activation of
b-catenin/wnt pathway [3–6]. Interestingly, recent
epidemiological studies show that variants of CaSR
from the most common diplotype are significantly
associated with the risk of advanced adenoma [23].
In this study, we showed that extracellular Ca2þ or
CaSR agonists (Gd3þ and neomycin) enhanced the
cytotoxic response of human colon adenocarcinoma
cells to MMC and 5-FU and modulated the expres-
sion of molecules involved in the cellular sensitivity
or resistance to these cytotoxic drugs. This enhanc-
ing and modulating effect of extracellular Ca2þ or
Gd3þ requires a functional CaSR because knocking
down CaSR expression abrogated the effect of extra-
cellular Ca2þ or Gd3þ. In addition, CaSR negative
cells were found to be resistant to cytotoxic drugs.
We hypothesize that these modulating effects of
extracellular Ca2þ (or Gd3þ) are directly linked to the
function of this ligand/receptor system in differ-
entiation control. Ca2þ inhibits cell growth and
induces differentiation in colon adenocarcinoma
cells [2–6]. TS is a key enzyme involved in the de
novo synthesis of DNA and is the molecular target of
5-FU [24,25]. 5-FU poisons TS, disrupts DNA syn-
thesis and kills cells. Cancer cells that express a high
level of TS circumvent the efficacy of 5-FU and are
relatively resistant to this drug [26,27]. Because Ca2þ
induces growth inhibition and differentiation, there
is less de novo synthesis of DNA in growth inhibited
and differentiated cells. Thus, the level of TS
expression is reduced and the reduction in TS
expression is linked to growth inhibition and differ-
entiation induction. Reduced TS expression may be
directly responsible for the increase in sensitivity to
5-FU. Increased expression of survivin is also asso-
ciated with resistance to cytotoxic drugs and cell
proliferation [18–20]. Likewise, survivin level is
suppressed in cells that are more differentiated and
growth inhibited. The suppression of TS and survivin
expression together may be responsible for the
dramatic increase in sensitivity to 5-FU while the
suppression of survivin expression alone may also
contribute to the increase in sensitivity to MMC. It is
well established that survivin is an anti-apoptotic
protein and high level of survivin expression is
known to block the ease in which the apoptotic
process is induced and resistance to apoptosis is
known to translate into anti-cancer drug resistance
[17–19]. Because CaSR activation down-regulates
the expression of survivin, it is likely that an
induction in the ease of apoptosis is an underlying
mechanism in the promotion of a cytotoxic
response. The modulation of survivin is not uniquely
associated with the CBS cells. We have now also
observed down-regulation of survivin upon CaSR
activation in the other cell lines (not shown). It
should be pointed out that CaSR function may be
dependent on the cells and tissues in which it is
expressed. For example, CaSR is also involved in
regulating osteoclast differentiation [28] and pro-
motes apoptosis in a variety of cell type [29,30]. In
fibroblasts, however, CaSR regulates cell survival and
is anti-apoptotic [31].
NQO1 is a cytosolic chemoprotective enzyme that
catalyzes the metabolic detoxification of quinones
and protects cells against redox cycling and oxidative
stress [32–34]. It is not clear why NQO1 expression is
increased in growth inhibited and differentiated
cells. Nevertheless, NQO1 is a key enzyme involved
in the bioreductive activation of MMC. It has
been shown that reduced level of bioreductive
activation of MMC is responsible for MMC resistance
in colon cancer cells [13]. Therefore, Ca2þ (or Gd3þ)
induced up-regulation of NQO1 expression may be
directly responsible for the increase in sensitivity to
MMC while down-regulation of survivin expression
may also contribute to the overall increase in
sensitivity to MMC. Currently, MMC is not partic-
ular useful in treating colon cancer. It is intriguing
that CaSR activation could modulate the expression
of NQO-1 that is involved in MMC activation and
promoted sensitivity to this drug. Whether MMC
in combination with 5-FU along with CaSR activa-
tion will improve on therapeutic efficacy is not
known and will require further studies. From a
clinical perspective, TS is linked to resistance to
5-FU while survivin is linked to resistance to variety
of cytotoxic drugs. Thus, down-modulation of
TS and survivin together should offer a significant
advantage to a therapeutic regimen containing 5-FU.
5-FU (in combination with oxaliplatin and/or irino-
tecan) is the main stay of cytotoxic therapy for colon
cancer. Therefore, it is very likely that CaSR activa-
tion will promote sensitivity to a regimen containing
5-FU and other cytotoxics. The type of regimen (5-FU
in combination with other drugs) that will provide
the maximum benefit upon CaSR activation is,
however, is not known and will require further
investigation.
In the CaSR knocked-down cells, we observed an
increase in the expression of TS and survivin. CaSR,
in response to extracellular Ca2þ, may down-regulate
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the basal expression of these molecules. When CaSR
expression is reduced or lost, the cellular response
to extracellular Ca2þ may be attenuated and thus,
allowing for a higher expression of TS and survivin.
CaSR and extracellular Ca2þ may function together
to modulate the basal expression of these molecules.
If CaSR can be activated in vivo in colon carcinomas,
it should improve therapeutic efficacy. A variety of
agonists can activate the CaSR. Thus, it is attractive to
develop nontoxic CaSR agonists for this purpose. An
alternative approach is to bypass the receptor and
activate post-receptor mechanisms that are respon-
sible for the modulation of TS and NQO-1. This
approach is particularly attractive because it should
also kill cancer cells that do not express CaSR.
In summary, extracellular Ca2þ (or Gd3þ) enhanced
the cytotoxic response of human colon carcinoma
cells to 5-FU and MMC and modulated the expres-
sion of TS, NQO1 and survivin which are intimately
associated with sensitivity or resistance to these
drugs. These effects of extracellular Ca2þ is CaSR
dependent because knocking down the expression of
CaSR by shRNA abrogated both the enhancement of
cytotoxic response to drugs and the modulating
effects on the expression of TS, NQO1 and survivin.
CaSR negative cells were found to be more resistant
to these cytotoxic drugs.
ACKNOWLEDGMENTS
This work was supported by National Institute of
Health, Bethesda, MD (R01 CA47775).
REFERENCES
1. Brown EM, Pollak M, Hebert SC. The extracellular calcium-
sensing receptor: Its role in health and disease. Ann Rev Med
1998;49:15–29.
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